Globenewswireยท2025-10-29 01:39Core Viewpoint - A class action securities fraud lawsuit has been filed against Savara Inc. by Pomerantz LLP, correcting a previous statement regarding the filing firm [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for shareholders affected by alleged securities fraud occurring between March 4, 2024, and May 23, 2025 [2]. - The complaint alleges that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [3]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay the submission timeline previously communicated to investors [3]. Group 2: Implications for Investors - The delay in regulatory approval for MOLBREEVI increases the likelihood that Savara would need to raise additional capital, impacting shareholder value [3]. - Shareholders who suffered losses during the relevant timeframe are encouraged to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5]. - The firm has been consistently ranked among the top securities litigation firms in the United States, emphasizing its expertise in complex securities cases [5].